{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:48:24Z","timestamp":1792709304160,"version":"4.5.0"},"reference-count":26,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Renal cell carcinoma accounts for nearly 15,000 deaths annually in the US, and approximately 30\u201340% of patients present with metastatic disease (mRCC). The advent of immune checkpoint inhibitors (IO) and tyrosine kinase inhibitors (TKI) has revolutionized the treatment paradigm of patients with mRCC. However, the role of cytoreductive nephrectomy (CN) in the IO-TKI era, particularly for rare and understudied histologies such as non-clear-cell RCC, remains poorly understood. Methods: We conducted a retrospective cohort study of patients with metastatic non-clear-cell RCC. Patients were stratified by receipt of CN. Baseline demographic, clinical, histologic, and metastatic site variables were collected. Overall survival was analyzed using Kaplan\u2013Meier methods and compared with the log-rank test. Cox proportional hazards regression was performed to identify independent predictors of survival, including CN, systemic therapy, year of diagnosis, histology, and metastatic sites. Results: Among 2753 patients with metastatic nccRCC, 1654 (60.1%) underwent CN and 1099 (39.9%) did not undergo CN. The 2-year and 5-year OS rates were 35.52% and 19.22% in the CN group versus 18.53% and 7.47% in the non-CN group (p &lt; 0.001). In the doubly robust IPTW-weighted multivariable Cox regression analysis, CN was associated with improved overall survival, corresponding to a 40% lower risk of death compared with no CN (HR 0.60, 95% CI 0.54\u20130.66; p &lt; 0.001). Additionally, more recent treatment eras were associated with progressively improved overall survival, with patients diagnosed between 2015 and 2017 and 2018 onward demonstrating significantly improved OS compared with those diagnosed between 2004 and 2014. Conclusions: Our study demonstrates that CN was associated with improved OS in patients with non-clear-cell mRCC by reducing the risk of death by 40% after adjusting for baseline characteristics. These findings emphasize the role of CN even in the IO-TKI era for the management of patients with non-clear-cell mRCC. However, these findings should be interpreted in the context of the retrospective study design, potential selection bias, and lack of granular systemic therapy data within the NCDB.<\/jats:p>","DOI":"10.3390\/cancers18132114","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:27:37Z","timestamp":1782746857000},"page":"2114","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Role of Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Carcinoma in the Era of Emerging Systemic Therapy: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"18","author":[{"given":"Mohammad Arfat","family":"Ganiyani","sequence":"first","affiliation":[{"name":"Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Narvel","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee, WI 53226, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9535-780X","authenticated-orcid":false,"given":"Arjun Pon","family":"Avudaiappan","sequence":"additional","affiliation":[{"name":"Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7780-9963","authenticated-orcid":false,"given":"Mrudula","family":"Thiriveedi","sequence":"additional","affiliation":[{"name":"Decatur Morgan Hospital, Decatur, AL 35601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Javid","family":"Raja Iyub","sequence":"additional","affiliation":[{"name":"Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manas","family":"Pustake","sequence":"additional","affiliation":[{"name":"Texas Tech University Health Sciences Center, El Paso, TX 79905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Jatwani","sequence":"additional","affiliation":[{"name":"School of Medicine and Health Sciences, George Washington University, Washington, DC 20037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murugesan","family":"Manoharan","sequence":"additional","affiliation":[{"name":"Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Garje","sequence":"additional","affiliation":[{"name":"Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"ref_1","first-page":"e70043","article-title":"Cancer Statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1200\/JCO.2005.07.055","article-title":"Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience","volume":"23","author":"Patard","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"E371","DOI":"10.5489\/cuaj.9041","article-title":"2024 CUA-KCRNC Expert Report: Management of Non-Clear Cell Renal Cell Carcinoma","volume":"18","author":"Graham","year":"2024","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e438642","DOI":"10.1200\/EDBK_438642","article-title":"Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances","volume":"44","author":"Salgia","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","article-title":"A Comparison of Sunitinib with Cabozantinib, Crizotinib, and Savolitinib for Treatment of Advanced Papillary Renal Cell Carcinoma: A Randomised, Open-Label, Phase 2 Trial","volume":"397","author":"Pal","year":"2021","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.24.00767","article-title":"Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma","volume":"42","author":"Barata","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaoncol.2018.5543","article-title":"Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial","volume":"5","author":"Bex","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.euo.2019.03.007","article-title":"Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"2","author":"Graham","year":"2019","journal-title":"Eur. Urol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Zhao, Z., Wu, W., Duan, X., Zeng, G., and Liu, Y. (2019). The Value of Cytoreductive Nephrectomy on the Survival of Metastatic Renal Carcinoma Patients Based on the Number of Site-Specific Metastases. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0215861"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.33696\/immunology.6.202","article-title":"Cytoreductive Nephrectomy Following Immunotherapy: Evolution, Pearls, and Pitfalls of Treatment","volume":"6","author":"Davis","year":"2024","journal-title":"J. Cell. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma","volume":"379","author":"Ravaud","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.5152\/tud.2021.21006","article-title":"Current Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma","volume":"47","author":"Slots","year":"2021","journal-title":"Turk. J. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"11795549241272447","DOI":"10.1177\/11795549241272447","article-title":"The Role of Surgery in Metastatic Renal Cell Carcinoma in 2024","volume":"18","author":"Leung","year":"2024","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/iju.15594","article-title":"The Role of Cytoreductive Nephrectomy in the Era of Immune Checkpoint Inhibitors: A Review of Current Evidence and Ongoing Trials","volume":"32","author":"Hara","year":"2025","journal-title":"Int. J. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1007\/s00345-020-03107-0","article-title":"Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Outcome of Patients Treated with a Multidisciplinary, Algorithm-Driven Approach","volume":"38","author":"Liu","year":"2020","journal-title":"World J. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.euo.2020.12.010","article-title":"Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-Institutional Registry (REMARCC)","volume":"4","author":"Marchioni","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_17","first-page":"166","article-title":"Kidney Cancer Research Network of Canada (KCRNC) Consensus Statement on the Role of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma","volume":"13","author":"Mason","year":"2019","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"659","DOI":"10.6004\/jnccn.2009.0046","article-title":"Non-Clear Cell Renal Cancer: Features and Medical Management","volume":"7","author":"Heng","year":"2009","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1470-2045(23)00276-0","article-title":"Pembrolizumab plus Lenvatinib as First-Line Therapy for Advanced Non-Clear-Cell Renal Cell Carcinoma (KEYNOTE-B61): A Single-Arm, Multicentre, Phase 2 Trial","volume":"24","author":"Albiges","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.eururo.2024.04.025","article-title":"Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial","volume":"86","author":"Fitzgerald","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.annonc.2025.03.016","article-title":"Prospective Randomized Phase-II Trial of Ipilimumab\/Nivolumab versus Standard of Care in Non-Clear Cell Renal Cell Cancer-Results of the SUNNIFORECAST Trial","volume":"36","author":"Bergmann","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1001\/jamaoncol.2025.1891","article-title":"First-Line Therapy for Advanced Non-Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis","volume":"11","author":"Petrelli","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"103923","DOI":"10.5527\/wjn.v14.i2.103923","article-title":"Survival and Treatment of Stage IV Renal Cell Carcinoma in Academic vs Non-Academic Medical Centers","volume":"14","author":"Weng","year":"2025","journal-title":"World J. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Iisager, L., Ahrenfeldt, J., Donskov, F., Ljungberg, B., Bex, A., Lund, L., Lyskj\u00e6r, I., and Fristrup, N. (2024). Multicenter Randomized Trial of Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma Receiving Checkpoint Inhibitors: The NORDIC-SUN-Trial. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-11987-3"},{"key":"ref_25","unstructured":"SWOG Cancer Research Network (2026, April 07). Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04510597."},{"key":"ref_26","unstructured":"Yonsei University (2026, April 07). The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in Immuno-Oncology Era: SEVURO-CN Trial, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05753839."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2114\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T06:14:08Z","timestamp":1782800048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":26,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18132114"],"URL":"https:\/\/doi.org\/10.3390\/cancers18132114","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]}}}